Abstract
Dysfunctions in nucleic acid-sensing Toll-like receptors (TLRs) disrupt nucleic acid tolerance, leading to systemic lupus erythematosus (SLE). Here, we report a novel homozygous gain-of-function p.R95L mutation in the TLR chaperone protein UNC93B1 in an SLE patient. Bulk and single-cell transcriptional analysis of the patient’s peripheral blood mononuclear cells (PBMCs) revealed significantly elevated inflammation in T cells and myeloid cells due to enhanced dendritic cells function. The UNC93B1 R95L mutation leads to hyperactivation of TLR7/8, but not TLR3/9, upon stimulation with specific agonists in vitro. Transgenic Unc93b1R95L/R95L mice develop inflammatory and autoimmune phenotypes, and the upregulation of inflammatory signaling differs among organs, with a specific contribution of malfunctioned T cells and B cells. In human and mouse cell lines, the UNC93B1 R95L mutation promotes TLR7/8 signaling by enhancing its binding to ssRNA, without affecting TLR7/8 translocation. Overall, our results elucidate the pathology of organs and the immunological profiles of immune cell populations in the development of SLE caused by the UNC93B1 R95L mutation through the TLR7/8 axis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The works of QZ were supported by grants 82225022, 32141004 and 32321002 from The National Natural Science Foundation of China. The works of X.Y. were supported by the Major Program of the National Natural Science Foundation of China (82394424), the National Natural Science Foundation of China (82471844), the Hundred-Talent Program of Zhejiang University and Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2021R01012). The works of PT were supported by grants 82201926 and 82471814 from The National Natural Science Foundation of China, BX2021259 and 2021M702852 from China Postdoctoral Science Foundation. The works of RW were supported by grant 82300893 from The National Natural Science Foundation of China.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethic committee of the institutional review boards of the Children's Hospital of Zhejiang University School of Medicine in China gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors jointly supervised this work: Qing Zhou, Panfeng Tao, Xiaomin Yu E-mail: taopanfeng1109{at}gmail.com; yuxiaomin78{at}gmail.com
Data Availability
All data produced in the present study are available upon reasonable request to the authors
